{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-013711","form_type":"8-K","ticker":"TELO","cik":"0001971532","company_name":"Telomir Pharmaceuticals, Inc.","filed_at":"2025-06-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.600112+00:00","generated_at":"2026-05-19T22:54:22.062169+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Telomir-1 preclinical study in Werner Syndrome model shows 100% survival, reverses epigenetic aging","bullets":["Oral Telomir-1 restored healthy DNA methylation at two CpG island regions, resetting the epigenetic clock.","Telomere length increased beyond levels seen in healthy controls.","Full reversal of muscle and body weight loss in the Werner Syndrome animal model.","100% survival in Telomir-1-treated animals vs 15% mortality in untreated controls.","Oxidative stress markers reduced by up to 50%."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-013711","json":"https://secwatch.observer/filing/0001641172-25-013711.json","markdown":"https://secwatch.observer/filing/0001641172-25-013711.md","text":"https://secwatch.observer/filing/0001641172-25-013711.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1971532/000164117225013711/0001641172-25-013711-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1971532/000164117225013711/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T22:54:22.062169+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}